Literature DB >> 12382227

The Acute Dialysis Quality Initiative--part II: patient selection for CRRT.

Rinaldo Bellomo1, Derek Angus, Robert A Star.   

Abstract

The delivery of optimal acute dialytic support requires that the correct patients be selected for such treatment in a timely fashion and that such treatment be delivered at the appropriate dose, for an appropriate length of time, and for the appropriate indications. The Acute Dialysis Quality Initiative sought to address these issues through an expert-enhanced review of the literature. This article represents a condensation of its findings with regard to patients selection for CRRT, indications for initiation of treatment, transition to other treatments, cessation of treatment, and availability of continuous therapy. The article offers recommendations for clinical practice based on the findings of the expert group. It also offers suggestions and sets priorities for future research in this important area of critical care nephrology. Copyright 2002 by the National Kidney Foundation, Inc.

Entities:  

Mesh:

Year:  2002        PMID: 12382227     DOI: 10.1053/jarr.2002.35570

Source DB:  PubMed          Journal:  Adv Ren Replace Ther        ISSN: 1073-4449


  3 in total

1.  Alkaline phosphatase for treatment of sepsis-induced acute kidney injury: a prospective randomized double-blind placebo-controlled trial.

Authors:  Peter Pickkers; Suzanne Heemskerk; Jeroen Schouten; Pierre-François Laterre; Jean-Louis Vincent; Albertus Beishuizen; Philippe G Jorens; Herbert Spapen; Michael Bulitta; Wilbert H M Peters; Johannes G van der Hoeven
Journal:  Crit Care       Date:  2012-01-23       Impact factor: 9.097

2.  Cystatin C is not a reliable marker of residual glomerular filtration rate during continuous renal replacement therapy.

Authors:  H D Kiers; R de Sévaux; P Pickkers
Journal:  Intensive Care Med       Date:  2011-08-18       Impact factor: 17.440

3.  Continuous renal replacement therapy for the treatment of acute kidney injury.

Authors:  Woo Kvun Bae; Dae Hun Lim; Ji Min Jeong; Hae Young Jung; Seong Ku Kim; Jeong Woo Park; Eun Hui Bae; Seong Kwon Ma; Soo Wan Kim; Nam Ho Kim; Ki Chul Choi
Journal:  Korean J Intern Med       Date:  2008-06       Impact factor: 3.165

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.